19 June 2013 - 19 June 2013 - Irish Amarin Corporation plc (NASDAQ:AMRN) said today it had been notified that a US FDA advisory committee will meet on 16 October regarding the supplemental New Drug Application (sNDA) for Vascepa (icosapent ethyl) capsules.

The sNDA is seeking approval for the use of Vascepa as an adjunct to diet in the treatment of adult patients with high triglycerides (TG ≥200 mg/dL and